Introduction
============

Chronic kidney disease (CKD) is defined as abnormalities in kidney structure or function that have been present for over 3 months, with implications for health.[@b1-tcrm-12-1517],[@b2-tcrm-12-1517] All stages of CKD are associated with increased health care use and Medicare expenditure.[@b3-tcrm-12-1517] At present, the incidence of CKD is rapidly increasing.[@b4-tcrm-12-1517] It has been reported that there is one medication-related problem for every 2.7 dialysis patients.[@b5-tcrm-12-1517] Despite widespread evidence in the literature, dosing errors in patients with CKD still occur at an alarming rate.[@b6-tcrm-12-1517]

Impaired renal function can have pronounced effects on the pharmacokinetics of many medicines as a result of alterations in absorption, distribution, metabolism, and excretion. The most common alteration is a decrease in drug excretion, resulting in increased plasma concentrations and heightened risk of drug toxicity. Therefore, there is an increased risk of drug-related problems such as the use of contraindicated medicines and inappropriate dosages, with potentially adverse outcomes.[@b7-tcrm-12-1517],[@b8-tcrm-12-1517] It is essential to select the appropriate medicine and individualize the dosage in order to avoid the occurrence of adverse drug reaction (ADR).

For CKD patients, inappropriate medication may be generated when the medicine has not been adjusted to appropriate dosage or some nephrotoxic medicine has been prescribed. As a result, the risk of ADR further increases.[@b9-tcrm-12-1517] Compared with patients with normal renal function, CKD patients are more prone to experiencing ADRs.[@b10-tcrm-12-1517],[@b11-tcrm-12-1517] Appropriate medicine selection and dosage for patients with CKD are important to avoid unwanted medicine effects and ensure optimal patient outcomes. Efforts to reduce dosing errors can lower the rate of ADR, reduce costs, and improve the overall delivery of health care.[@b12-tcrm-12-1517]--[@b15-tcrm-12-1517]

Up to now, a number of studies have been reported on the use of medicines in patients with renal dysfunction. However, they only focused on a certain type of medicine. Investigations of antibiotics were most reported for renal insufficiency,[@b16-tcrm-12-1517]--[@b21-tcrm-12-1517] followed by nonsteroidal anti-inflammatory drugs and angiotensin-converting enzyme inhibitors.[@b22-tcrm-12-1517],[@b23-tcrm-12-1517] As reported in China, dosage errors for antibiotics prescribed for CKD patients were in the range of 38.85%--60.3%.[@b20-tcrm-12-1517],[@b21-tcrm-12-1517] To the best of the authors' knowledge, there was no study that comprehensively analyzed the inappropriate medicine use in CKD patients at tertiary teaching hospitals. Therefore, the authors retrospectively investigated medicine prescriptions in the hospital's CKD patients, and then the inappropriate medication prescriptions were analyzed and classified.

Methods
=======

Study design and patient selection
----------------------------------

A cross-sectional study was conducted in a Chinese tertiary teaching hospital from November 1 to December 1, 2014. The hospital is a comprehensive and information-based hospital with 2,500 beds, where a multidisciplinary team of diverse professionals provide a range of health-care services for approximately 114,000 inpatients each year. During the data collection period, all the patients hospitalized were included in this study. Data regarding prescribing of medications were collected from the hospital information system, then for the further data analysis.

Patients were included if they were: 1) CKD patients with serum creatinine level above the normal value according to the hospital's criterion of 45--84 µmol/L for women and 59--104 µmol/L for men; 2) aged ≥18 years; 3) had body mass index ≥18.5 kg/m^2^ and ≤24.9 kg/m^2^. The exclusion criteria were: patients receiving hemodialysis, peritoneal dialysis, or renal replacement therapy.

Ethical approval was acquired from the First Affiliated Hospital of ZheJiang University's research review committee. All patients enrolled in this study provided written informed consent for their information to be used for this study.

Data collection and evaluation on appropriateness of prescriptions
------------------------------------------------------------------

Data on the characteristics of patients and medication prescriptions were extracted from the hospital information system. Two clinical pharmacists independently collected data by using a structured format; any dispute was resolved through discussion or with the assistance of another clinical pharmacist. The content included demographic variables, name of the medication, dosage forms, dosages, frequency, and number of medicines prescribed. Demographic information about a patient, including gender, age, weight, and serum creatinine, was used to determine the creatinine clearance rate (Ccr), which was calculated by using the Cockcroft--Gault equation: $$\begin{array}{l}
{\text{If}\ \text{male}:\ \text{Ccr=}\frac{(140 - \text{age}) \times \text{Weight}}{72 \times \text{SCr}}} \\
{\text{If}\ \text{female}:\ \text{Ccr=}\frac{(140 - \text{age)×Weight}}{72 \times \text{SCr}} \times 0.85} \\
\end{array}$$where Ccr is expressed in milliliters per minute, age in years, weight in kilograms, and serum creatinine in milligrams per deciliter. Despite the limitation of this equation, it is the most prevalent method for determining medicine dosage based on kidney function in medication instruction (MI). Then stages of CKD were graded according to Ccr by the National Kidney Foundation Kidney Disease Outcomes Quality Initiative guidelines.

To evaluate the appropriateness of prescriptions for each enrolled patient, the prescribed medicines were compared with MI approved by the China Food and Drug Administration. Evaluation of the inappropriateness of prescriptions was based on three aspects, namely unreasonable medicine dosage, contraindicated, and cautiously used medicine. Unreasonable medicine dosages imply medicines prescribed at a dose that is more or less than what is recommended by MI. Contraindicated used medicines imply the medicines should have been avoided in CKD patients, while cautiously used medicines imply the medicines should be used carefully in the CKD patients. Thereafter, the prevalence of inappropriate prescriptions in CKD patient and the related medications were classified and analyzed.

Statistical analyses
--------------------

Descriptive statistics were performed, response associations between stage of CKD and frequency of inappropriate medication prescriptions were determined by using Spearman's rank correlation coefficient (*r*), with *P*-value \<0.05 as significant correlation. The analysis was performed by Stata 12.0 software (StataCorp LP, College Station, TX, USA).

Results
=======

Patient characteristics
-----------------------

In all, 9,589 hospitalized patients were included in the study by primary screening. Then, 202 CKD patients involving 1,733 lines of medicine prescriptions were enrolled on the basis of inclusion and exclusion criteria in this study. Basic characteristics of included patients are presented in [Table 1](#t1-tcrm-12-1517){ref-type="table"}. The majority of the 202 CKD patients (64.36%) were male, with a mean age of 64.83±15.46 years, and the average number of medications per patient was 8.58±5.06. According to the classification of CKD, 54.46% CKD patients were in the G3 stage of renal dysfunction. Moreover, the ward distribution of 202 enrolled patients was investigated. As shown in [Figure 1](#f1-tcrm-12-1517){ref-type="fig"}, 23.76% patients were treated in the nephrology department.

Frequency of inappropriate prescriptions in CKD patients
--------------------------------------------------------

As exhibited in [Table 2](#t2-tcrm-12-1517){ref-type="table"}, among the 1,733 lines of medicine prescriptions for 202 CKD patients, 263 lines (15.18%) were inappropriate prescriptions. Among these inappropriate prescriptions, unreasonable medicine dosages, contraindicated, and cautiously used medicines accounted for 56 (3.23%), 46 (2.65%), and 161 (9.29%), respectively. This study found that the inappropriateness of unreasonable medicine dosages and contraindicated used medicines were mostly administered in the G4 and G5 stages of CKD, while the cautiously used medicines were administered in all the stages of CKD.

The frequency of inappropriate medication prescriptions in patients with various severity of CKD was also analyzed, as shown in [Table 2](#t2-tcrm-12-1517){ref-type="table"}. Spearman's rank correlation coefficient implied that there were significant correlations between the severity of renal insufficiency and frequency of inappropriate medication prescriptions (*P*=0.02, *r*=0.056).

Medications related with inappropriate prescriptions in CKD patients
--------------------------------------------------------------------

Among the inappropriate medication prescriptions in CKD patients, nutraceutical and electrolytes (n=65, 24.71%), cardiovascular drugs (n=61, 23.19%), and antimicrobial drugs (n=55, 20.91%) represented the three top medicine categories. As shown in [Figure 2](#f2-tcrm-12-1517){ref-type="fig"}, antimicrobial drugs (n=50, 89.29%) were the most common category of medicines associated with unreasonable dosage, followed by cardiovascular drugs (n=4, 7.14%). Endocrine and metabolic drugs (n=17, 36.96%) were the most common contraindicated drug categories used in renal dysfunction; next were central nervous system (n=6, 13.04%) and hematologic (n=6, 13.04%) drug categories. Nutraceuticals and electrolytes (n=60, 37.27%), diuretics (n=28, 17.39%), and cardiovascular drugs (n=24, 14.91%) were the top three categories of medicines that correlated with cautiously used medicines in CKD patients.

Taking specific medicines into consideration, carbohydrate--electrolyte solution (n=17, 6.46%), potassium chloride (n=16, 6.08%), and spironolactone (n=14, 5.32%) were the top three medicines of inappropriate medication prescriptions. As shown in [Table 3](#t3-tcrm-12-1517){ref-type="table"}, piperacillin--tazobactam (n=12, 21.43%), acarbose (n=7, 15.22%), and carbohydrate--electrolyte solution (n=17, 7.98%) were found to be the most common medications associated with inappropriate prescriptions in unreasonable dosage used, contraindicated, and cautiously used medicines, respectively. The evaluation on appropriateness of carbohydrate--electrolyte solution and potassium chloride was based on the serum electrolyte levels according to the standard in the hospital.

Discussion
==========

Because most medicines are predominantly eliminated in urine, renal function is expected to play an important role in their disposition. Understanding and quantification of the impact of various degrees of kidney function on medicine exposure is important to help with appropriate medicine selection and dose adjustment decisions in CKD patients. However, reports on the analysis of inappropriate medication prescriptions in CKD patients remain limited. As far as the authors know, this study is the first to assess the frequency of inappropriate medication prescriptions in CKD patients in a Chinese tertiary teaching hospital.

Optimizing medicines dosage and choice in CKD could reduce the incidence of adverse drug events (ADEs).[@b24-tcrm-12-1517],[@b25-tcrm-12-1517] Hassan et al reported that hospital pharmacists can contribute to a reduction in the incidence of ADEs in patients with renal impairment.[@b26-tcrm-12-1517] It is possible that physicians pay more attention to patients' diagnosis than details of medication prescribing. However, impaired renal function can be associated with alterations of drug pharmacokinetics; awareness of proper medicine selection and dosage individualization is of critical importance, as it can avoid the occurrence of ADEs and the risk of therapeutic failure.

This study sheds light on a problem that cannot be ignored in CKD patients. According to this study, unreasonable medicine dosage (n=56, 3.23%), contraindicated (n=46, 2.65%), and cautiously used medicines (n=161, 9.29%) were common inappropriate phenomenon in CKD patients. Spearman's rank correlation analysis revealed that the frequency of inappropriate medication prescriptions was positively corrected with the severity of renal insufficiency (*P*=0.02, *r*=0.056). A possible explanation for this could be that the nature and opportunistic diagnosis of CKD resulted in the higher prevalence of inappropriate prescribing.[@b27-tcrm-12-1517],[@b28-tcrm-12-1517] Other contributing factors reported included prescribers' poor knowledge of medications requiring dosage adjustment, underestimation of potential adverse events, and lack of evidence-based data to guide prescribers on dosage adjustments as well as lack of quantitative data in the available MI.[@b29-tcrm-12-1517],[@b30-tcrm-12-1517] It is necessary that physicians should consider patients' renal function when prescribing for CKD patients.

It was found that for unreasonable medicine dosage use, antimicrobial drugs accounted for the highest proportion. Most of the antimicrobial drugs, such as β-lactams, are eliminated by the kidneys in an unchanged condition, so dosage adjustment is frequently required in patients with renal insufficiency. However, antibiotic dosages in six prescriptions were lower than the recommendation of MI, for example, piperacillin--tazobactam (n=4) and cefuroxime (n=1), these β-lactams antibiotics required dosage adjustment only when the Ccr level was \<40 mL/min and 20 mL/min, respectively. In addition, metronidazole (n=1), which is mainly metabolized in the liver and eliminated by the kidneys, needed no dosage adjustment under renal insufficiency. An incorrect dosage adjustment may result in lower dosage and poor treatment effect. One explanation that maybe advanced for this incorrect adjustment is that, the physician was not familiar with the pharmacokinetics of the prescribed medicines mentioned earlier. Correspondingly, the dosages of the other prescriptions (n=44) were higher than the recommendation of MI, such as quinolones, cephalosporins, entecavir, adefovir dipivoxil, and so on, which are predominantly excreted by the kidneys; normal dosage may cause potential drug accumulation and adverse reactions.

It is worth noting that antidiabetic drugs were the most common contraindicated used medicines in CKD patients, such as acarbose and metformin. In CKD patients, metformin may cause life-threatening lactic acidosis,[@b31-tcrm-12-1517] so current medicine labels regard the use of metformin as contraindicated in patients with serum creatinine level \>1.5 mg/dL for males and 1.4 mg/dL for females. A software program for guiding dosage adjustment to minimize the risk of drug accumulation was reported;[@b25-tcrm-12-1517] however, it was not available at all locations. Therefore, the use of metformin in patients with mild renal impairment was subject to debate. Acarbose is a kind of α-glucosidase inhibitor that delays the absorption of intestinal carbohydrates to achieve decreasing blood glucose. The relationship between the use of this medicine in CKD patients and the risk of ADEs was seldom reported. However, the MI clearly pointed out that acarbose should be avoided in patients with Ccr \<25 mL/min. It is possible that drug accumulation may result in serious flatulence and diarrhea.

A Spanish university hospital reported that 54.1% of acute renal failure (ARF) cases were drug related. In addition, patients with drug-related ARF episodes were more prone to having cardiovascular events. The medicines most frequently involved were diuretics, agents acting on the renin--angiotensin system, immunosuppressant, β-blocking agents, calcium channel blockers, contrast media, and non-steroidal anti-inflammatory drugs.[@b32-tcrm-12-1517] Each of these medicines may affect renal function due to several mechanisms and, when used in combination, can lead to increased risk of ARF. So, these medicines should be used carefully in CKD patients. In this study, diuretic (n=28), nonsteroidal anti-inflammatory drugs (n=12), and angiotensin-converting enzyme inhibitors (n=6) accounted for 1.62%, 0.69%, and 0.35%, respectively, of all prescriptions about inappropriate medication prescriptions. However, the combination of these medicines was not found in this study. It is worth reminding that these medicines should be carefully prescribed in CKD patients. Moreover, close monitoring should be emphasized.

It is worth reminding that nutraceutical and electrolytes were the most cautiously and contraindicated used medicines, including enteral nutritional emulsion, carbohydrate--electrolyte solution, potassium chloride, and so on. In CKD patients, drugs prone to accumulation may lead to electrolyte disturbance, such as hyperkalemia and hypercalcemia. Therefore, monitoring serum electrolyte levels should get particular attention. If the laboratory value exhibit in the normal level, this was not considered a potential risk factor.

Limitations
===========

This study has a number of limitations. Even though it is a single-center study, the authors think the results may be extrapolated to other hospitals of similar characteristics. In addition, it is possible that some concealed CKD patients were omitted, because the inclusion criteria were based on serum creatinine and not on Ccr. Also, the study did not assess confounding factors such as patients' complication to medicine therapy. Finally, because it was a retrospective study, the relationship between inappropriate medicine use and occurrence of ADEs was not analyzed.

Conclusion
==========

This study confirms that unreasonable medicine dosage, contraindicated, and cautiously used medicines were highly prevalent inappropriate prescriptions in CKD patients. With regard to these results, multifaceted measures should be applied, such as the integration of a decision support system about automatic hints and warnings into a computerized physician order entry system. Moreover, as reported, the intervention of a clinical pharmacist can also reduce the rates of inappropriate prescriptions. Putting into practice all the aforementioned facts could lead to an improvement in the quality of care provided to CKD patients.
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###### 

Characteristics of enrolled CKD patients

  Stage of CKD (n, %)   Gender, n (%)   Age, mean ± SD   Medicines used, mean ± SD   
  --------------------- --------------- ---------------- --------------------------- -----------
  G2 (29, 14.36)        20 (68.97)      9 (31.03)        64.56±15.46                 8.46±5.00
  G3a (65, 32.18)       45 (69.23)      20 (30.77)       64.54±15.39                 8.49±5.02
  G3b (45, 22.28)       30 (66.67)      15 (33.33)       64.80±15.45                 8.54±5.07
  G4 (44, 21.78)        27 (61.36)      17 (38.64)       64.76±15.47                 8.45±4.99
  G5 (19, 9.40)         8 (42.11)       11 (57.89)       64.12±15.70                 8.66±5.12
  Total (202, 100)      130 (64.36)     72 (35.64)       64.83±15.46                 8.58±5.06

**Abbreviations:** CKD, chronic kidney disease; SD, standard deviation.

###### 

Inappropriate prescriptions in various severity CKD patients

  Stage of CKD (n, %)   Unreasonable dosage, n (%)   Contraindicated used medicines n (%)   Cautiously used medicines, n (%)   Inappropriate medication prescription, n (%)   Total medication prescription (n)
  --------------------- ---------------------------- -------------------------------------- ---------------------------------- ---------------------------------------------- -----------------------------------
  G2 (29, 14.36)        1 (0.57)                     1 (0.57)                               19 (10.86)                         21 (12)                                        175
  G3a (65, 32.18)       16 (3.14)                    7 (1.37)                               48 (9.41)                          71 (13.92)                                     510
  G3b (45, 22.28)       11 (2.79)                    5 (1.27)                               31 (7.87)                          47 (11.93)                                     394
  G4 (44, 21.78)        25 (5.68)                    21 (4.77)                              48 (10.91)                         94 (21.36)                                     440
  G5 (19, 9.40)         3 (1.40)                     12 (5.61)                              15 (7.01)                          30 (14.02)                                     214
  Total                 56 (3.23)                    46 (2.65)                              161 (9.29)                         263 (15.18)                                    1,733

**Note:** Spearman's rank correlation analysis revealed that the frequency of inappropriate medication prescriptions was positively corrected with the severity of renal insufficiency (*P*=0.02, *r*=0.056).

**Abbreviation:** CKD, chronic kidney disease.

###### 

Top five medicines associated with inappropriate medication prescriptions in CKD patients

  Ranking   Frequency (n, %)                                                          
  --------- --------------------------------------- --------------------------------- ------------------------------------------------
  First     Piperacillin--tazobactam (12, 21.43%)   Acarbose (7, 15.22%)              Carbohydrate--electrolyte solution (17, 7.98%)
  Second    Levofloxacin (7, 12.5%)                 Metformin (3, 6.52%)              Potassium chloride (16, 7.51%)
  Third     Ceftazidime (6, 10.71%)                 Lamivudine (3, 6.52%)             Spironolactone (14, 6.57%)
  Fourth    Adefovir dipivoxil (3, 5.36%)           Colchicines (3, 6.52%)            Calcium gluconate (10, 4.69%)
  Fifth     Entecavir (3, 5.36%)                    Rosuvastatin Calcium (2, 4.35%)   Isosorbide mononitrate (8, 3.76%)

**Abbreviation:** CKD, chronic kidney disease.
